215 related articles for article (PubMed ID: 8977503)
1. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen.
Hammann C; Kämmerer R; Gerber M; Spertini F
J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503
[TBL] [Abstract][Full Text] [Related]
2. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
[TBL] [Abstract][Full Text] [Related]
3. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
4. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens.
Zuber P; Pécoud A
J Allergy Clin Immunol; 1988 Oct; 82(4):590-4. PubMed ID: 2902114
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
Richard C; Bibas P; Lablache-Combier M; Allaire C
J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
[TBL] [Abstract][Full Text] [Related]
7. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
Pécoud A; Zuber P; Kolly M
Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
[TBL] [Abstract][Full Text] [Related]
9. Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.
Dake Y; Enomoto T; Cheng L; Enomoto K; Shibano A; Ikeda H; Yoda S; Yajin S; Sakota T; Yamanishi E
Allergol Int; 2006 Dec; 55(4):373-8. PubMed ID: 17130679
[TBL] [Abstract][Full Text] [Related]
10. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests.
Rimås M; Kjellman NI; Blychert LO; Björkstén B
Allergy; 1990 Jan; 45(1):18-21. PubMed ID: 1968726
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of levocabastine in conjunctival provocation studies.
Janssens M
Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
[TBL] [Abstract][Full Text] [Related]
12. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.
Orfeo V; Vardaro A; Lena P; Mensitieri I; Tracey M; De Marco R
Eur J Ophthalmol; 2002; 12(4):262-6. PubMed ID: 12219994
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
Allaire C; Siou-Mermet R; Bassols A
J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
[TBL] [Abstract][Full Text] [Related]
14. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis.
Ciprandi G; Cerqueti PM; Sacca S; Cilli P; Canonica GW
Ann Allergy; 1990 Aug; 65(2):156-8. PubMed ID: 1974402
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
Abelson MB; George MA; Schaefer K; Smith LM
J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
Greiner JV; Minno G
Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
[TBL] [Abstract][Full Text] [Related]
18. Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy of seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe.
Kremer B; Tündermann A; Goldschmidt O
Arzneimittelforschung; 1998 Sep; 48(9):924-30. PubMed ID: 9793620
[TBL] [Abstract][Full Text] [Related]
19. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis.
Abelson MB; Weintraub D
Eur J Ophthalmol; 1994; 4(2):91-101. PubMed ID: 7950341
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S; Greiner JV; Discepola M; Finegold I
Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
